CSPG4 and neoplasm: Based on emerging pre-clinical efficacy, immune activatory functions and promising clinical studies of the first IgE class antibody specific for tumor-associated antigens13,14,16,17,24,37, here we designed CSPG4 IgE by combining the CSPG4-specific variable domains of a mouse clone (225.28), with a human IgE backbone.